Pharmaceutical Executive July 15, 2024
In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, discusses how their AI/ML approach differs and the advantages it offers in terms of uncovering novel treatment opportunities.
Current drug discovery often focuses on a single molecular target. How does Cellarity’s AI/ML approach differ, and what advantages does it offer in terms of uncovering novel treatment opportunities?
At Cellarity, we are harnessing the power of AI and MultiMix data to drive a radically new approach to joint discovery. And what’s very specific about our approach, about the Cellarity platform, is that we are shifting the starting point of drug discovery. We are shifting the starting point from a single molecular target to the cellular dysfunction underlying...
Today's Sponsors
Today's Sponsor